AR069085A1 - Anticuerpos especificos de los peptidos beta- amiloides y sus usos como agentes de diagnostico o drogas - Google Patents

Anticuerpos especificos de los peptidos beta- amiloides y sus usos como agentes de diagnostico o drogas

Info

Publication number
AR069085A1
AR069085A1 ARP080104708A ARP080104708A AR069085A1 AR 069085 A1 AR069085 A1 AR 069085A1 AR P080104708 A ARP080104708 A AR P080104708A AR P080104708 A ARP080104708 A AR P080104708A AR 069085 A1 AR069085 A1 AR 069085A1
Authority
AR
Argentina
Prior art keywords
mammal
antibody
abeta8
level
peptides
Prior art date
Application number
ARP080104708A
Other languages
English (en)
Spanish (es)
Inventor
Eugeen Vanmechelen
Andre Delacourte
Pierre Gronet
Veronique Blanchard-Bregeon
Luc Bluee
Marie Gompel
Nicolas Sergeant
Laurent Pradier
Original Assignee
Sanofi Aventis
Inst Nat Sante Rech Med
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069085(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis, Inst Nat Sante Rech Med, Innogenetics Nv filed Critical Sanofi Aventis
Publication of AR069085A1 publication Critical patent/AR069085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP080104708A 2007-10-29 2008-10-28 Anticuerpos especificos de los peptidos beta- amiloides y sus usos como agentes de diagnostico o drogas AR069085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119537 2007-10-29

Publications (1)

Publication Number Publication Date
AR069085A1 true AR069085A1 (es) 2009-12-30

Family

ID=38925731

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104708A AR069085A1 (es) 2007-10-29 2008-10-28 Anticuerpos especificos de los peptidos beta- amiloides y sus usos como agentes de diagnostico o drogas

Country Status (27)

Country Link
US (1) US8343493B2 (de)
EP (1) EP2205633A1 (de)
JP (1) JP5421277B2 (de)
KR (1) KR20100097651A (de)
CN (1) CN101883792B (de)
AP (1) AP2957A (de)
AR (1) AR069085A1 (de)
AU (1) AU2008317705B2 (de)
CA (1) CA2703825A1 (de)
CL (1) CL2008003197A1 (de)
CO (1) CO6270369A2 (de)
CR (1) CR11396A (de)
EA (1) EA201070539A1 (de)
EC (1) ECSP10010142A (de)
HN (1) HN2010000880A (de)
IL (1) IL205398A0 (de)
MA (1) MA31793B1 (de)
MX (1) MX2010004660A (de)
MY (1) MY155144A (de)
NI (1) NI201000075A (de)
NZ (1) NZ585000A (de)
TN (1) TN2010000197A1 (de)
TW (1) TW200936605A (de)
UA (1) UA103602C2 (de)
UY (1) UY31433A1 (de)
WO (1) WO2009056490A1 (de)
ZA (1) ZA201002989B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4275747A2 (de) 2016-07-19 2023-11-15 Duke University Therapeutische anwendungen von cpf1-basierter genomeditierung

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177954A1 (en) * 2007-01-05 2012-02-28 Univ Zuerich Method of providing disease-specific binding molecules and targets
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
EP2949666B1 (de) 2008-12-19 2018-12-19 Biogen International Neuroscience GmbH Menschliche anti-alpha-synuclein-antikörper
KR101755737B1 (ko) 2009-09-11 2017-07-07 프로비오드룩 아게 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체
EP2542579A1 (de) 2010-03-03 2013-01-09 Boehringer Ingelheim International GmbH Biparatopische abeta-bindende polypeptide
EP2511296A1 (de) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antikörper, Kit und Verfahren zur Bestimmung von Amyloidpeptiden
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
EP2847217B1 (de) 2012-05-10 2017-10-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin KONFORMATIONSSPEZIFISCHE ANTIKÖRPER GEGEN Amyloid (BETA)-OLIGOMERE
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US10774120B2 (en) * 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
MA49947B1 (fr) 2017-08-22 2023-03-31 Biogen Ma Inc Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
WO2023111168A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag A novel antibody for detection of amyloid beta 42 (aβ42)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4275747A2 (de) 2016-07-19 2023-11-15 Duke University Therapeutische anwendungen von cpf1-basierter genomeditierung

Also Published As

Publication number Publication date
CA2703825A1 (en) 2009-05-07
IL205398A0 (en) 2010-12-30
US20110059092A1 (en) 2011-03-10
JP2011502139A (ja) 2011-01-20
MX2010004660A (es) 2010-07-30
NZ585000A (en) 2012-08-31
NI201000075A (es) 2010-09-23
CN101883792A (zh) 2010-11-10
EA201070539A1 (ru) 2010-10-29
CN101883792B (zh) 2014-08-27
KR20100097651A (ko) 2010-09-03
JP5421277B2 (ja) 2014-02-19
CR11396A (es) 2012-10-18
AU2008317705B2 (en) 2014-06-05
AP2957A (en) 2014-08-31
MA31793B1 (fr) 2010-10-01
ZA201002989B (en) 2011-07-27
CO6270369A2 (es) 2011-04-20
ECSP10010142A (es) 2010-07-30
US8343493B2 (en) 2013-01-01
CL2008003197A1 (es) 2010-01-15
TN2010000197A1 (en) 2011-11-11
UY31433A1 (es) 2009-05-29
EP2205633A1 (de) 2010-07-14
UA103602C2 (ru) 2013-11-11
MY155144A (en) 2015-09-15
WO2009056490A1 (en) 2009-05-07
AP2010005249A0 (en) 2010-06-30
HN2010000880A (es) 2014-03-10
AU2008317705A1 (en) 2009-05-07
TW200936605A (en) 2009-09-01

Similar Documents

Publication Publication Date Title
AR069085A1 (es) Anticuerpos especificos de los peptidos beta- amiloides y sus usos como agentes de diagnostico o drogas
Smith et al. Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy
TWI549966B (zh) 測定澱粉樣肽之抗體、套組及方法
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
CO6231037A2 (es) Anticuerpos anti-hepcidina y usos de los mismos
Oda et al. Localization of nephritis-associated plasmin receptor in acute poststreptococcal glomerulonephritis
Li et al. BAR domain-containing FAM92 proteins interact with Chibby1 to facilitate ciliogenesis
BR0310088A (pt) Pré-direcionamento de droga por meio de anticorpos biespecìficos e constructos haptênicos compreendendo um veìculo peptìdico e o(s) agente(s) ativo(s)
AR085198A1 (es) Composicion farmaceutica
ATE497508T1 (de) Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
CO6230998A2 (es) Un metodo para aislar una molecula de enlace especifico dericado de desordenes asociados a proteinas, moleculas de enlace especificas y objetivos
JP6307509B2 (ja) 腎機能の診断若しくは監視又は腎機能障害の診断方法
Rasmussen et al. A novel antihuman C3d monoclonal antibody with specificity to the C3d complement split product
Cabral et al. Membrane-associated aquaporin-1 facilitates osmotically driven water flux across the basolateral membrane of the thick ascending limb
AU2015343202A1 (en) PIF binding as a marker for immune dysregulation
ES2846836T3 (es) Método para predecir la sensibilidad a una terapia combinada con lenvatinib y everolimus
CN110678757B (zh) 诊断或监测肾功能或诊断肾功能障碍的方法
Kovačević et al. Monoclonal antibody 26 cross-reactive with β2-glycoprotein I affects human trophoblast invasion in vitro
Paule et al. Cytoskeletal remodelling proteins identified in fetal-maternal interface in pregnant women and rhesus monkeys
US20230013244A1 (en) Pif binding as a marker for immune dysregulation
Zeng et al. Integrin α5 is involved in fibronectin-induced human extravillous trophoblast invasion
Márquez et al. Physiologically induced restructuring of focal adhesions causes mobilization of vinculin by a vesicular endocytic recycling pathway
US9222947B2 (en) Anti-sAPPβ antibody
US20230028696A1 (en) Predictive Markers of Psychosis
Wang et al. Endothelial angiotensin II generation induced by placenta-derived factors from preeclampsia

Legal Events

Date Code Title Description
FB Suspension of granting procedure